Prof. Neri spent most of his scientific / research carrier in the field of imaging informatics, gastrointestinal imaging and head and neck imaging.
The most recent activities have been focused on the development and validation of imaging biomarkers, imaging biobanks and artificial intelligence.
Prof. Neri is coordinator of the Tuscany project NAVIGATOR (An Imaging Biobank to Precisely Prevent and Predict cancer, and facilitate the Participation of oncologic patients to Diagnosis and Treatment), that aims to set up an open imaging biobank with a Virtual Research Environment (VRE) available to extract gold-standard and novel imaging biomarkers; to create and test digital patient models mining cancer phenotypes, stratified risks and responsivity to therapy.
Prof. Neri leads the Imaging Laboratory (http://imaginglab.med.unipi.it/) of the Department of Translational Research, a multidisciplinary laboratory dedicated to frontier research in the study of biomedical images. The activities of the Lab focus on the development and validation of imaging biomarkers, imaging biobanks and artificial intelligence.
The Imaging Laboratory is partner in 4 Horizon 2020 projects:
PRIMAGE, PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers.
PRIMAGE is one of the largest and more ambitious European research projects in medical imaging, artificial intelligence and childhood cancer.
https://www.primageproject.eu/
EuCanImage, Towards a European cancer imaging platform for enhanced Artificial Intelligence in oncology.
EuCanImage will build a highly secure, federated and large-scale cancer imaging platform, with capabilities that will greatly enhance the potential of Artificial Intelligence in oncology.
The CHAIMELEON project aims to develop a structured repository of health images and related clinical and molecular data on the most prevalent cancers in Europe: lung, breast, prostate and colorectal.
This EU-wide interoperable repository will greatly facilitate and contribute to the development and validation of AI tools for improved cancer management.
PROCANCER-I, An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum: In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices lead to overdiagnosis and overtreatment, necessitating more effective tools for discriminating between aggressive and non-aggressive disease. The EU-funded ProCAncer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment.